海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

002399 海普瑞

午间休市 08-14 11:30:00

{"stockData":{"symbol":"002399","market":"SZ","secType":"STK","nameCN":"海普瑞","latestPrice":13.35,"timestamp":1755146013000,"preClose":13.4,"halted":0,"volume":3955320,"delay":0,"changeRate":-0.0037,"floatShares":1247000000,"shares":1467000000,"eps":0.4419,"marketStatus":"午间休市","change":-0.05,"latestTime":"08-14 11:30:00","open":13.43,"high":13.49,"low":13.28,"amount":52938900,"amplitude":0.0157,"askPrice":13.36,"askSize":7,"bidPrice":13.35,"bidSize":40,"shortable":0,"etf":0,"ttmEps":0.4419,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1755147600000},"marketStatusCode":3,"adr":0,"adjPreClose":13.4,"symbolType":"stock","openAndCloseTimeList":[[1755135000000,1755142200000],[1755147600000,1755154800000]],"highLimit":14.74,"lowLimit":12.06,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1467296204,"isCdr":false,"pbRate":1.6,"roa":"--","peRate":30.210455,"roe":"1.28%","epsLYR":0.4408,"committee":0.515,"marketValue":19588000000,"turnoverRate":0.0032,"status":1,"hkstockBrief":{"symbol":"09989","market":"HK","secType":"STK","nameCN":"海普瑞","latestPrice":6.44,"timestamp":1755143964972,"preClose":6.53,"halted":0,"volume":700000,"delay":0,"premium":"-55.91"},"floatMarketCap":16650000000},"requestUrl":"/m/hq/s/002399","defaultTab":"news","newsList":[{"id":"2553428942","title":"异动快报：海普瑞（002399）7月21日11点26分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2553428942","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2553428942?lang=zh_cn&edition=full","pubTime":"2025-07-21 11:30","pubTimestamp":1753068638,"startTime":"0","endTime":"0","summary":"证券之星7月21日盘中消息，11点26分海普瑞触及涨停板。目前价格13.82，上涨10.03%。其所属行业化学制药目前上涨。领涨股为一品红。该股为肝素，化学原料药，创新药概念热股，当日肝素概念上涨1.46%，化学原料药概念上涨1.14%，创新药概念上涨1.03%。7月18日的资金流向数据方面，主力资金净流出186.5万元，占总成交额3.23%，游资资金净流出126.23万元，占总成交额2.18%，散户资金净流入312.73万元，占总成交额5.41%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025072100010233.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09989","002399","BK0239","BK0070","BK0188","BK1191"],"gpt_icon":0},{"id":"2552644463","title":"海普瑞(002399.SZ)：H1710完成I期临床试验首例受试者入组及首次给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2552644463","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2552644463?lang=zh_cn&edition=full","pubTime":"2025-07-18 16:34","pubTimestamp":1752827646,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞 公告，公司自主研发的创新候选药物注射用H1710I期临床试验已完成首例受试者入组及首次给药。H1710通过抑制乙酰肝素酶的活性和表达，展现出抗肿瘤作用。本次临床试验为开放、剂量递增的Ia期临床研究，评价H1710在晚期实体瘤患者中的安全性、耐受性和初步抗肿瘤活性，为H1710的首次人体试验，计划在三家研究中心开展，预计入组约36名患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1319434.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09989","BK1191","002399","BK1583","BK1141","BK0188","BK0239","03347","BK1576","BK0070"],"gpt_icon":0},{"id":"2550651116","title":"海普瑞新提交2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2550651116","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550651116?lang=zh_cn&edition=full","pubTime":"2025-07-10 05:07","pubTimestamp":1752095259,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日深圳市海普瑞药业集团股份有限公司新提交2件商标注册申请。商标申请详情如下：今年以来深圳市海普瑞药业集团股份有限公司新申请注册商标6件，截止目前公司共持有注册商标149件，另有12件商标尚在注册申请中。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025071000003375.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0188","BK0239","002399","BK1191","09989"],"gpt_icon":0},{"id":"2549107347","title":"海普瑞新提交2件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2549107347","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549107347?lang=zh_cn&edition=full","pubTime":"2025-07-06 05:07","pubTimestamp":1751749637,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日深圳市海普瑞药业集团股份有限公司新提交2件商标注册申请。商标申请详情如下：今年以来深圳市海普瑞药业集团股份有限公司新申请注册商标2件，截止目前公司共持有注册商标149件，另有8件商标尚在注册申请中。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070600000702.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0070","BK0239","BK0188","002399","09989","BK1191"],"gpt_icon":0},{"id":"2548001150","title":"海普瑞：坪山园区预灌封制剂生产线获EMA许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2548001150","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548001150?lang=zh_cn&edition=full","pubTime":"2025-07-01 20:51","pubTimestamp":1751374289,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞06月30日在投资者关系平台上答复投资者关心的问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100035454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0070","BK0239","09989","002399","BK1191"],"gpt_icon":0},{"id":"2548001166","title":"海普瑞：公司将持续聚焦主业","url":"https://stock-news.laohu8.com/highlight/detail?id=2548001166","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548001166?lang=zh_cn&edition=full","pubTime":"2025-07-01 20:51","pubTimestamp":1751374288,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞(002399)06月30日在投资者关系平台上答复投资者关心的问题。投资者提问：公司有进军其他行业的打算吗？毕竟现在很多国家重点扶持的行业发展势头强劲，公司有没有考虑过鸡蛋不要放在一个篮子里？海普瑞回复：您好，公司将持续聚焦主业，巩固全球销售网络和全肝素产业链垂直打通的领先优势，加大市场拓展力度，探索商业合作模式，感谢您的关注。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025070100035453.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09989","BK0070","002399","BK1191","BK0239","BK0188"],"gpt_icon":0},{"id":"2545847686","title":"港股异动 | 海普瑞(09989)午前涨超3% 近日收到EMA签发关于依诺肝素钠注射液新增生产商的批准通知","url":"https://stock-news.laohu8.com/highlight/detail?id=2545847686","media":"智通财经","labels":["corporation","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545847686?lang=zh_cn&edition=full","pubTime":"2025-06-24 11:42","pubTimestamp":1750736554,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，海普瑞午前涨超3%，截至发稿，涨3.09%，报5.33港元，成交额872.01万港元。消息面上，海普瑞发布公告，公司近日收到欧洲药品管理局签发的关于依诺肝素钠注射液新增生产商的批准通知。据介绍，海普瑞坪山园区新建预灌封制剂生产线项目于2022年正式启动，首期新建三条预灌封生产线设计产能为3.3亿支╱年，其按照中国、欧美药品法规标准设计建造，用于生产依诺肝素钠预灌封注射液。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308820.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0070","EMA","BK4081","BK1191","09989","002399","BK0239","BK0188"],"gpt_icon":0},{"id":"2545149658","title":"海普瑞(09989)将于7月7日派发末期股息每10股2.5元","url":"https://stock-news.laohu8.com/highlight/detail?id=2545149658","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545149658?lang=zh_cn&edition=full","pubTime":"2025-06-23 16:32","pubTimestamp":1750667556,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)发布公告，该公司将于2025年7月7日派发截至2024年12月31日止年度的末期股息每10股2.5元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1308387.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0070","002399","BK1191","09989","BK0188"],"gpt_icon":0},{"id":"2544549439","title":"海普瑞(002399.SZ)：依诺肝素钠注射液获得EMA新增生产商批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2544549439","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544549439?lang=zh_cn&edition=full","pubTime":"2025-06-17 16:51","pubTimestamp":1750150299,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(002399.SZ)发布公告，公司近日收到欧洲药品管理局(“EMA”)签发的关于依诺肝素钠注射液新增成品制造商的批准通知。本次公司坪山园区预灌封制剂生产线获得EMA的许可，标志着公司坪山园区生产的依诺肝素钠注射液已获得在欧洲经济区(EEA)实现商业化的资格，本次获批将为公司进一步推进制剂国际化战略提供更加充足的产能保障，切实提高公司市场竞争力;同时，依托强大的预灌针生产能力，以及公司成熟的自营销售网络及渠道，公司助力中国药企药品出海欧美市场的战略将得到有力的支持和推动，对公司未来业务拓展有深远且积极的影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1306215.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","EMA","002399","BK0188","BK1191","BK4081","BK0070","09989"],"gpt_icon":0},{"id":"2544938756","title":"京东方、合肥产投、超越摩尔等机构押注，海普瑞完成B+轮战略融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2544938756","media":"猎云网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2544938756?lang=zh_cn&edition=full","pubTime":"2025-06-17 09:53","pubTimestamp":1750125233,"startTime":"0","endTime":"0","summary":"在各界合作伙伴和战略股东的支持下，海普瑞将进一步推动技术创新和产业布局，加速打造国产半导体超纯管阀领军企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506170953599782a71c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506170953599782a71c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["002399","BK0239","561980","BK0188","BK0070"],"gpt_icon":0},{"id":"2543868188","title":"海普瑞完成B+轮融资，加速打造国产半导体超纯管阀领军企业","url":"https://stock-news.laohu8.com/highlight/detail?id=2543868188","media":"爱集微","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2543868188?lang=zh_cn&edition=full","pubTime":"2025-06-13 19:11","pubTimestamp":1749813075,"startTime":"0","endTime":"0","summary":"近日，海普瑞完成B+轮融资，此轮融资得到京东方、合肥产投、超越摩尔及某一体化存储器制造公司的大力支持。海普瑞为国内首家研发及生产半导体级PVDF和PFA超高纯阀门、管、接头、仪器仪表的公司，主营业务涵盖晶圆制造工艺中液体输送与控制系统，在半导体湿法制程中实现超纯水、电子级化学品的输送、循环和控制。产品广泛应用于晶圆厂超纯水系统、化学品供液系统、湿法设备及湿电子化学品等领域。在各界合作伙伴和战略股东的支持下，海普瑞将进一步推动技术创新和产业布局，加速打造国产半导体超纯管阀领军企业。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613191231951afd43&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250613191231951afd43&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","BK0070","002399","09989","561980","159582","BK0188"],"gpt_icon":0},{"id":"2538475447","title":"上海普瑞邦克软件技术有限公司成长沙银行全面预算管理系统建设项目中标候选人","url":"https://stock-news.laohu8.com/highlight/detail?id=2538475447","media":"DoNews","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2538475447?lang=zh_cn&edition=full","pubTime":"2025-05-28 20:10","pubTimestamp":1748434203,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025年05月27日，湖南省长沙市，长沙银行股份有限公司发布了全面预算管理系统建设项目的中标候选人公示。该项目于2025年05月27日在长沙银行21楼完成开标与评标，采用综合评估法进行评选。上海普瑞邦克软件技术有限公司以2780000元的报价成为第一中标候选人，信雅达科技股份有限公司和北京元年科技股份有限公司分别位列第二、第三名，对应报价为2880000元和2820000元。公示期从2025年05月27日至2025年05月30日。若无异议，招标人将确定第一名中标候选人为最终中标人。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052820110297687da3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025052820110297687da3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0188","002399","BK0278","BK0070","601577","BK0239"],"gpt_icon":0},{"id":"2537864979","title":"海普瑞将于7月22日派发末期股息每10股2.7165港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537864979","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537864979?lang=zh_cn&edition=full","pubTime":"2025-05-23 08:34","pubTimestamp":1747960440,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　海普瑞（09989）公布，将于2025年7月22日派发末期股息每10股2.7165港元。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-05-23/doc-inexpeui0971050.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["002399","BK0070","BK1191","BK0188","BK0239","09989"],"gpt_icon":0},{"id":"2537592945","title":"海普瑞(09989)将于7月22日派发末期股息每10股2.7165港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2537592945","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2537592945?lang=zh_cn&edition=full","pubTime":"2025-05-22 19:57","pubTimestamp":1747915077,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)公布，将于2025年7月22日派发末期股息每10股2.7165港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1296551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09989","BK0188","BK0239","BK0070","BK1191","002399"],"gpt_icon":0},{"id":"2529960071","title":"海普瑞(002399.SZ)发布一季度业绩，归母净利润1.57亿元，同比增长1.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529960071","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529960071?lang=zh_cn&edition=full","pubTime":"2025-04-24 19:22","pubTimestamp":1745493778,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(002399.SZ)发布2025年一季度报告，第一季度，公司实现营业收入13.94亿元，同比增长1.53%。归属于上市公司股东的净利润1.57亿元，同比增长1.00%。归属于上市公司股东的扣除非经常性损益的净利润1.89亿元，同比增长20.27%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09989","002399"],"gpt_icon":0},{"id":"2529604530","title":"海普瑞(09989)：Ivenoxin获南非健康产品监管局上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2529604530","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529604530?lang=zh_cn&edition=full","pubTime":"2025-04-24 18:24","pubTimestamp":1745490240,"startTime":"0","endTime":"0","summary":"海普瑞发布公告，公司全资子公司深圳市天道医药有限公司生产的依诺肝素钠注射液已获得南非健康产品监管局上市许可。此次获批意味着集团依诺肝素钠制剂可进入南非市场销售，进一步提升了集团依诺肝素钠制剂在全球的市场份额。董事会认为，这是集团制剂业务国际化布局的又一重要成果，再次印证了集团开拓海外市场的能力。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-04-24/doc-ineuhiqv2857399.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09989","BK0070","002399","BK1191","BK0239","BK0188"],"gpt_icon":0},{"id":"2529606213","title":"海普瑞(09989)发布一季度业绩，归母净利润1.57亿元，同比增长1%","url":"https://stock-news.laohu8.com/highlight/detail?id=2529606213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529606213?lang=zh_cn&edition=full","pubTime":"2025-04-24 18:23","pubTimestamp":1745490195,"startTime":"0","endTime":"0","summary":"智通财经APP讯，海普瑞(09989)发布2025年第一季度业绩，营业收入13.94亿元，同比增长1.53%;归属于上市公司股东的净利润1.57亿元，同比增长1%;基本每股收益0.1067元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284097.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09989","002399"],"gpt_icon":0},{"id":"2529603247","title":"海普瑞最新公告：依诺肝素钠注射液获得南非药品注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2529603247","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529603247?lang=zh_cn&edition=full","pubTime":"2025-04-24 18:01","pubTimestamp":1745488878,"startTime":"0","endTime":"0","summary":"海普瑞公告称，全资孙公司天道医药收到南非卫生产品管理局签发的依诺肝素钠注射液批准通知。许可有效期为五年。本次获批将进一步提升公司依诺肝素钠制剂在全球的市场占有率，是公司制剂业务国际化布局的重要成果。截至公告日，该产品已在全球超过50个国家及地区获批上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025042400030864.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09989","BK0070","002399","BK1191","BK0239","BK0188"],"gpt_icon":0},{"id":"2517193729","title":"海普瑞：公司将持续加强市值管理工作争取为股东带来更好回报","url":"https://stock-news.laohu8.com/highlight/detail?id=2517193729","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517193729?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:51","pubTimestamp":1741179096,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞(002399)03月04日在投资者关系平台上答复投资者关心的问题。投资者提问：工资如何维护投资者的利益？是否看好公司未来前景？能否推行员工持股股计划四期，能否回购公司股份注销？能否推动高管增持股份计划？能否2024年度分红扩股？海普瑞回复：您好，公司始终坚持聚焦核心主业，提升公司内在价值，我们将持续加强市值管理工作，促进公司投资价值合理反映公司质量，争取为股东带来更好的回报。谢谢您的关注。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500038393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","002399","09989","BK0239","BK0188","BK0070"],"gpt_icon":0},{"id":"2517195619","title":"海普瑞：公司专注主业已建立全球销售网络和全肝素产业链领先优势","url":"https://stock-news.laohu8.com/highlight/detail?id=2517195619","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2517195619?lang=zh_cn&edition=full","pubTime":"2025-03-05 20:51","pubTimestamp":1741179092,"startTime":"0","endTime":"0","summary":"证券之星消息，海普瑞03月04日在投资者关系平台上答复投资者关心的问题。公司是否会进行投资？海普瑞回复：您好，公司专注主业，在肝素领域，我们已建立全球销售网络和全肝素产业链垂直打通的领先优势，核心产品依诺肝素钠制剂远销逾40个国家及地区。同时，我们持续探索合适机遇，如建立并推进与正大天晴、永太药业的商业合作，助力中国药企出海。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030500038389.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1191","BK0239","002399","BK0188","BK0070","09989"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1755146026930,"stockEarnings":[{"period":"1week","weight":0.0198},{"period":"1month","weight":0.0993},{"period":"3month","weight":0.2272},{"period":"6month","weight":0.3108},{"period":"1year","weight":0.3442},{"period":"ytd","weight":0.2801}],"compareEarnings":[{"period":"1week","weight":0.0136},{"period":"1month","weight":0.0465},{"period":"3month","weight":0.0895},{"period":"6month","weight":0.1006},{"period":"1year","weight":0.2844},{"period":"ytd","weight":0.099}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"深圳市海普瑞药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"0人","perCapita":"--","listingDate":"2010-05-06","address":"广东省深圳市南山区松坪山郎山路21号","registeredCapital":"146729万元","survey":"　　深圳市海普瑞药业集团股份有限公司的主营业务是肝素产业链，生物大分子CDMO和创新药物的投资，开发及商业化。公司的主要产品是依诺肝素钠制剂、肝素钠、依诺肝素钠原料药、大分子药物CDMO服务。公司旗下依诺肝素钠制剂自2016年通过集中审批程序（CP）在欧洲药品管理局（EMA）获得批准后，2020年在售全部5个规格率先通过国内仿制药质量和疗效一致性评价。凭借卓越的产品质量和稳定的疗效，公司旗下依诺肝素钠制剂累计出口量稳居国内前列。","listedPrice":148},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.7","shortVersion":"4.34.7","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"海普瑞,002399,海普瑞股票,海普瑞股票老虎,海普瑞股票老虎国际,海普瑞行情,海普瑞股票行情,海普瑞股价,海普瑞股市,海普瑞股票价格,海普瑞股票交易,海普瑞股票购买,海普瑞股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"海普瑞(002399)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供海普瑞(002399)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}